[Home](https://github.com/mm80843/T3.5/blob/main/docs/index.md) >> Class: [RiskMitigation](https://github.com/mm80843/T3.5/tree/main/docs/RiskMitigation/index.md) >> Individual ID:PBN__RiskMitigation_2513 

# __Evaluate the difference in efficacy between symptomatic and asymptomatic individuals.__

## Category to which it belongs

* [Implement comprehensive, widespread testing and contact tracing programs to monitor and control the spread of the virus.](https://github.com/mm80843/T3.5/blob/main/docs/PBNCategory/PBN__PBNCategory_460.md)

## Closest similar item

* [Evaluate efficacy differences based on symptoms](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_1186.md)
* [Implement regular and widespread symptom monitoring and testing, both symptomatic and asymptomatic](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2036.md)
* [Promote awareness about asymptomatic transmission, encourage individuals to practice preventive measures regardless of symptoms](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2312.md)
* [Increase testing capacity to include testing of mild or asymptomatic individuals to obtain a more accurate assessment of the prevalence.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2560.md)
* [Conduct clinical trials to determine the efficacy of drug therapies, develop new therapeutics](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_1594.md)
* [Identify missing information and develop logical relations linking drugs, coronaviruses, and conditions for drug efficacy.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_1963.md)
* [Improve testing frequency and accuracy, conduct seroprevalence surveys.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2511.md)
* [Conduct more efficacy studies in clinical settings to evaluate the impact of these measures on tb transmission](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_1860.md)
* [Meta-analyses should carefully evaluate the quality and reliability of included studies and exclude studies with flawed or fraudulent data.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_3031.md)
* [Strengthen surveillance systems to actively detect and treat asymptomatic and unreported cases](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2830.md)

## Risks possibly mitigated by this Mitigation

* [Variation in protection against re-infections](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1891.md)

